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More than 150 point mutations have now been identified in the ATP7A gene. Most of these mutations lead to the
classic form of Menkes disease (MD), and a few lead to the milder occipital horn syndrome (OHS). To get a better
understanding of molecular changes leading to classic MD and OHS, we took advantage of the unique finding of
three patients with similar mutations but different phenotypes. Although all three patients had mutations located
in the splice-donor site of intron 6, only two of the patients had the MD phenotype; the third had the OHS
phenotype. Fibroblast cultures from the three patients were analyzed by reverse transcriptase (RT)–PCR to try to
find an explanation of the different phenotypes. In all three patients, exon 6 was deleted in the majority of the
ATP7A transcripts. However, by RT-PCR amplification with an exon 6–specific primer, we were able to amplify
exon 6–containing mRNA products from all three patients, even though they were in low abundance. Sequencing
of these products indicated that only the patient with OHS had correctly spliced exon 6–containing transcripts.
We used two different methods of quantitative RT-PCR analysis and found that the level of correctly spliced mRNA
in this patient was 2%–5% of the level found in unaffected individuals. These findings indicate that the presence
of barely detectable amounts of correctly spliced ATP7A transcript is sufficient to permit the development of the
milder OHS phenotype, as opposed to classic MD.
Introduction
Menkes disease (MD; MIM 309400) is a multisystemic
lethal disorder of copper metabolism inherited as an X-
linked recessive trait. The phenotypic features of MD
are dominated by severe neurological degeneration and
connective-tissue abnormalities (for review, see Di-
Donato and Sarkar 1997; Kodama et al. 1999). The
disease is caused by mutations in theATP7A gene, which
encodes a Cu-transporting P-type ATPase involved in
copper efflux from cells and in intracellular transport of
copper to copper-requiring proteins (for review, see Pena
et al. 1999). The ATP7A protein is localized to the trans-
Golgi membrane (Yamaguchi et al. 1996) but translo-
cates to the plasma membrane in response to increased
copper concentrations (Petris et al. 1996). To a large
extent, the clinical features of MD can be attributed to
malfunction of one or more copper-requiring enzymes,
such as lysyl oxidase, cytochrome c oxidase, and do-
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pamine b-hydroxylase, caused by the deficiency of
ATP7A (Kodama and Murata 1999).
In addition to the severe classic form of MD leading
to death in early childhood, milder forms are observed
in ∼5%–10% of the patients. Occipital horn syndrome
(OHS) is the mildest allelic form of MD (Proud et al.
1996), and we are aware of 35–40 affected individuals
in the world. The neurological symptoms of OHS pa-
tients are milder than those found in patients suffering
from MD, leading to a clinical picture mainly charac-
terized by connective-tissue manifestations.
To date, a total of 162 different mutations affecting
ATP7A has been identified in 192 unrelated MD pa-
tients with the classic severe form or with one of the
atypical phenotypes (reviewed in Tu¨mer et al. 1999).
Of these mutations, 7 were chromosome abnormalities
and 35 were partial gene deletions (unpublished data).
The total number of point mutations identified within
ATP7A is 120, and ∼30% of these are splice-site mu-
tations (Das et al. 1994, 1995; Kaler et al. 1994, 1995,
1996; Tu¨mer et al. 1994, 1996, 1997; Levinson et al.
1996; Ronce et al. 1997; Qi and Byers 1998; Z. Tu¨mer,
L. B. Møller, N. Horn, C. Lund, unpublished data).
Until now, seven point mutations have been reported
in patients who were diagnosed with OHS (Kaler et al.
1994; Das et al. 1995; Levinson et al. 1996; Ronce et
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al. 1997; Qi and Byers 1998); in five of these patients,
the mutations were at the consensus splice-site se-
quences affecting the normal RNA splicing (Kaler et al.
1994; Das et al. 1995; Qi and Byers 1998). The milder
phenotype of these patients could be explained by the
presence of lower amount of normal transcripts or the
presence of partially functional proteins.
To obtain a better understanding of the molecular
defects leading to one form of MD or another, we made
a comparative study of patients with similar ATP7A
mutations but different clinical outcomes. Such a study
requires identification of several mutations in a large
patient cohort. The possibility of finding similar mu-
tations leading to different phenotypes is not very high,
taking into account the rarity of MD and especially that
of OHS. However, we were able to make such a com-
parison, because we found one person with OHS and
two with MD, all with mutations affecting the same
splice-donor site of ATP7A.
The ATP7A-specific mRNAs produced in fibroblast
cultures from the three patients were characterized and
quantified by reveres transcriptase (RT)–PCR analysis
to search for an explanation of the very different phe-
notypes. Only the cells from the patient with OHS were
found to contain detectable amounts of correctly spliced
ATP7A mRNA, the amount of which was determined
by two different quantitative RT-PCR methods. One
method involved the use of homologous competitor
fragments (Siebert and Larrick 1992), whereas the other
involved the use of a LightCycler, a real-time fluores-
cence detection system (Wittwer et al. 1997). We found,
in agreement with previous studies, that the milder phe-
notype of the OHS patient could be correlated with the
presence of normal ATP7A mRNA. However, to our
surprise, the amount was only 2%–5% of the level
found in unaffected individuals.
Materials and Methods
Patients
The clinical symptoms of patient MD1 suggestedMD,
and he was referred to the John F. Kennedy Institute for
biochemical confirmation of the initial diagnosis when
he was 6 mo old. In the child’s neonatal period, hypo-
glycemia and repeated episodes of hypothermia were
present. At the age of 8 wk, he was hospitalized because
of feeding difficulties that were soon accompanied by
therapy-resistant seizures. At 10 wk of age, his hair
started to fall out. It was replaced by hair with an ab-
normal texture, raising suspicion of MD. Serum copper
and ceruloplasmin levels were very low. Over the next
few months, patient MD1 developed clinical features
typical of MD, including subdural hematomas, a high
arched palate, and wormian bones in the lambdoid su-
ture of the occipital region. Bladder diverticulae were
diagnosed at age 1.5 years. Copper histidine therapywas
initiated when he was 8 mo old and continued until his
death at age 21 mo. Copper incorporation studies con-
firmed the diagnosis of MD. Later, the patient’s mother
had an affected fetus diagnosed prenatally.
Patient MD2 was referred to the John F. Kennedy
Institute at age 2 years for biochemical confirmation of
the clinical diagnosis. At birth, a right-sided cephaloh-
ematoma was observed; the child had neonatal biliru-
binemia that did not require therapy. Hypothermia was
noted in the neonatal period and at age 1 year. By age
1 year, he had developed seizures and had symptoms of
MD including hair changes, connective-tissue abnor-
malities comprising bilateral inguinal hernias, and typ-
ical bone changes such as pectus excavatum. Serum cop-
per and ceruloplasmin values were low. He did not
receive any copper therapy, and he died at age 33 mo.
Copper-incorporation studies indicated MD. His fam-
ily’s history did not indicate that any members had suf-
fered from MD. Subsequent DNA analysis showed that
his mother did not carry the disease mutation.
Patient OS1 is presently aged 24 years. His clinical
picture was typical of OHS, including narrow thorax,
joint deformities, right-sided genital hernia, bladder div-
erticulae, vascular abnormalities, and chronic diarrhea.
The occipital horns that name the disease were diag-
nosed when the patient was 18 years of age; the horns
had a length of about 5 cm. The patient’s skin was dry,
loose, and hypopigmented and his hair was coarse, but
other changes typical of OHS were not obvious. Recent
complications were aneurysms of abdominal vessels,
hepatic artery, and splenic artery, which were treated
surgically. The patient was psychomotorically retarded,
with psychotic traits (manic-depressive behavior). He
was able to walk without support at age 3 years, and
he started talking at age 3.5 years. Serum copper and
ceruloplasmin levels were significantly below normal
(!10 mmol/liter and 0.15 g/liter, respectively). Copper-
incorporation studies showed abnormal accumulation
and retention, confirming that patient OS1 suffered from
a variant of MD. A brother had died at age 8 years; he
had had similar connective-tissue disturbances and
coarse hair but was more severely retarded than patient
OS1 (Mentzel et al. 1999).
Samples
Skin samples were collected from the three patients
for diagnostic investigation. Similar samples from un-
affected male patients were used as controls. The fibro-
blast cells were cultured in a 1:1 mixture of RPMI 1640
with 20 mM N-2-hydroxyethylpiperazine-N′-2-ethane
sulphonic acid buffer and nutrient mixture F-10 Ham’s
media, supplemented with 7.5%AmnioMax (Life Tech-
nologies) C100 supplement, 4% fetal calf serum, peni-
cillin, and streptomycin.
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Table 1
DNA Primers Used in PCR Reactions
Primer Name Sequence Comment
MNK-1 5′-GCTCTAGAGAAACGTTGAGAGGAGCAAT-3′ In exon 4 (forward direction); contains XbaI restriction site
MNK-2 5′-CCCAAGCTTTCACAGTGGCTCCAAATCCAAG-3′ In exon 6 (reverse direction); contains HindIII restriction site
MNK-3 5′-CAAAAAGCAGCCCAAGTACCTC-3′ In exon 4 (forward direction)
MNK-4 5′-GGTGGTTGCCAGCACAATCAGTACGTCC-3′ In exon 10 (reverse direction)
MNK-5 5′-CAGAAGGGTCACAGCAAAGG-3′ In exon 4 (forward direction)
MNK-6 5′-AGACAATCCTGGAAGAATCTGGCGC-3′ In exon 9 (reverse direction)
MNK-7 5′-GTGATAGAAAATGCTGAT-3′ In exon 6 (forward direction)
18S-1 5′-GGGGTACCATGCATGTCTAAGTACGCAC-3′ Contains KpnI restriction site
18S-2 5′-CCCAAGCTTGGACACTCAGCTAAGAGCATC-3′ Contains HindIII restriction site
GAPDH-1 5′-CCCAAGCTTTCCATGACAACTTTGGTATCGTGG-3′ Contains HindIII restriction site
GAPDH-2 5′-CCGGAATTCGTCGCTGTTGAAGTCAGAGGAGAC-3′ Contains EcoRI restriction site
PCR Amplifications
PCR reactions were generally performed in a reaction
mixture containing 10 mM Tris-HCl (pH 8.3), 50 mM
KCl, 1.5 mM MgCl2, and 0.01% gelatin, with addition
of primers, deoxynucleotides (dNTPs), and Taq poly-
merase (PE Biosystems), as indicated. Table 1 describes
the DNA oligonucleotides used as primers in PCR
reactions.
Detection of Mutations in ATP7A
Genomic DNA was isolated from cultured skin fibro-
blasts by the NaCl extraction method (Grimberg et al.
1989). Mutation screening was performed either by sin-
gle-strand conformational polymorphism as described
previously (Tu¨mer et al. 1997) or by dideoxy finger-
printing modified after Sarkar et al. (1992). In brief,
dideoxy fingerprinting was performed by PCR amplifi-
cation of each exon with the previously described prim-
ers (Tu¨mer et al. 1997). The PCR amplification of ge-
nomic DNA was performed in a total volume of 25 ml
containing 100 nM of each primer, 20 mM dNTP, and
0.25 U Taq polymerase. A set of termination products
was generated by performing a limited sequencing of the
amplified exon with a single dideoxy terminator, 32P-
labeled primer, and ThermoSequenase (United States Bi-
ochemical). The termination products were separated on
a 6% nondenaturing mutation detection enhancement
gel (FMC Bioproducts). Exons showing an abnormal
band pattern were sequenced directly without further
purification.
Preparation of RNA and cDNA
Total RNA or mRNA was isolated from 104–106 cells
of cultured skin fibroblasts with the RNeasy Mini Kit
(QIAgen) or MicroPoly(A) pure mRNA Isolation Kit
(Ambion), respectively. Total RNA was eluted in 50 ml,
whereas mRNA was eluted in 20 ml. Single-stranded
cDNA was synthesized by reverse transcription of 7.5
ml RNA in a total volume of 20 ml with Superscript II
RNase H Reverse Transcriptase (GibcoBRL) and a
mixture of random hexamer primers (Pharmacia). The
RNA used was isolated from the following cell lines:
B9729997H/B9836567H (control cells); D9523179H
(MD1 cells); D9626782H (OS1 cells); and 119310634H
(MD2 cells).
Characterization of ATP7A mRNA by RT-PCR
The cDNA amplifications were performed as nested
PCR reactions, except for the quantitative determina-
tions. The PCR amplification was done in a total volume
of 50 ml containing 100 nM of each primer, 100 mM
dNTP, and 2.5 U Taq polymerase. Two microliters of
cDNA was used as template in the first PCR reaction,
whereas 2 ml of the first PCR reaction was used as tem-
plate in the second and final PCR reaction. The PCR
primers used to analyze the skipping of exon 6 were
MNK-3 and MNK-4 in the first PCR reaction, then
MNK-5 and MNK-6 in the second (table 1). The PCR
primers used to specifically amplify exon 6–containing
products were MNK-4 and MNK-7 in the first PCR
reaction, then MNK-6 and MNK-7 in the second. PCR
amplifications were performed for 40 cycles (94C for
30 s, 60C for 1 min, and 72C for 1 min) followed by
7 min at 72C. The amplified products were separated
on a 3% Metaphor agarose gel (FMC Bioproducts) and
visualized by ethidium bromide staining.
Sequence Analysis of RT-PCR Products
The products were separated on a 1% agarose gel,
and the fragments were excised from the gel and eluted
in 50 ml of water at room temperature. Direct sequencing
of the eluted fragment was performed with Thermo-
Sequenase (United States Biochemical) and a [32P]-la-
beled primer.
Quantitative RT-PCR Analysis by Homologous
Competitor DNA
The relative amounts of exon 6–containing ATP7A
mRNAs in normal control cells and in cells from patient
OS1 were determined by competitive RT-PCR (Siebert
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and Larrick 1992). As a competitor, we used a homol-
ogous plasmid, pMNKD, which contained a segment of
ATP7A cDNA with a small internal deletion, that had
been engineered in vitro. The amount of ATP7AmRNA
was normalized to the amount of 18S rRNA in the same
sample, which was measured in parallel with the ho-
mologous competitor plasmid, p18SD. The PCR reac-
tions for determination of ATP7A transcript and 18S
rRNA were performed in separate tubes with the primer
pairs MNK-1 and MNK-2, and 18S-1 and 18S-2, re-
spectively. In both cases, fourfold serial dilutions of the
competitor DNA were added to PCR reactions contain-
ing equal amounts of target cDNA (2 ml of ATP7A
cDNA or 1 ml of a 100-fold dilution of 18S cDNA).
Because of the greater abundance of 18S rRNA com-
pared with ATP7A mRNA, much higher concentrations
of competitor DNA had to be used in the 18S reactions.
The PCR amplifications were performed in a total vol-
ume of 20 ml containing 500 nM of each primer, 80 mM
dNTP (for 18S) or 18 mM dNTP (for ATP7A), 2.5 U
Taq polymerase, and 0.01 mCi of a-[32P]-dCTP. PCR
amplifications were performed for 60 cycles (94C for
30 s, 60C for 1 min, and 72C for 1 min) followed by
7 min at 72C. The large number of cycles was required
to get sufficient signals for quantitation, as the amount
of exon 6–containing transcript in patient OS1 was very
low. The amplified products were separated on a 3%
agarose gel. The bands were visualized by staining with
ethidium bromide, and the amount of radioactivity in
each band was determined by a PhospoImager (Molec-
ular Dynamics).
Construction of Plasmids Encoding Homologous
Competitor Fragments
The ATP7A competitor plasmid, pMNKD, contained
a segment of ATP7A cDNA (1439–1821, numbered ac-
cording to Tu¨mer et al. 1995) with a 30-bp deletion
(1552–1581), which was introduced by gene SOEing
(Horton 1993). This 353-bp–long cDNA fragment was
amplified by use of the MNK-1 and MNK-2 primers
(table 1), digested with HindIII and XbaI, and ligated
into a pDP19 vector.
For construction of the 18S rRNA competitor plas-
mid, p18SD, a 735-bp PCR fragment (149–883,
numbered according to GenBank accession number
M10098) was amplified from cDNA derived from 18S
rRNA by use of the 18S-1 and 18S-2 primers (table 1).
The PCR product was cloned into pDP19 by use of
KpnI and HindIII restriction enzymes, and a deletion of
133 bp was subsequently introduced by excision of an
XbaI restriction fragment (263–395). The resulting plas-
mid thus contained a 602-bp 18S cDNA competitor
fragment.
Quantitative RT-PCR Analysis with a Real-Time
Fluorescence Detection System
Real-time quantitative PCR analysis was performed
with a LightCycler Instrument with the DNA Master
SYBR Green I mix according to the manufacturer’s pro-
tocol (Roche Molecular Biochemicals). SYBR Green I is
a double-strand–specific dye, and its fluorescence is
greatly enhanced by its binding to double-stranded
DNA. Thus, the amount of amplified PCR product can
be estimated during each cycle of amplification by its
fluorescence (Wittwer et al. 1997). PCR amplifications
were performed on twofold serial dilutions of cDNA
reverse transcribed fromOS1 or control mRNA samples.
The primers MNK-1 and MNK-2 were used for deter-
mination of the amount of ATP7A mRNA. The relative
amounts of glyceraldehyde phosphate dehydrogenase
(GAPDH) mRNA in the same RNA samples were de-
termined in parallel in separate tubes with the primers
GAPDH-1 and GAPDH-2 (table 1), which give rise to
a cDNA fragment of 376 bp (corresponding to 3978–
5447 in the genomic sequence with removal of intron;
GenBank accession number J04038). The PCR ampli-
fications were performed in a total volume of 20 ml con-
taining 2 ml of LightCycler DNA Master SYBR Green
I, 4 mM MgCl2, 10 mg bovine serum albumin, 500 nM
of each primer, and 5 ml of cDNA. The amplification
parameters used were as follows: preheating at 95C for
30 s, followed by 50 cycles of amplification (95C for
2 s, 60C for 7 s, 72C for 35 s, and 79C for 0 s, single-
acquisition mode), followed by extension (72C for 30
s), terminated by melting (95C for 0 s, 65C for 15 s,
and 95C for 0 s, continuous-acquisition mode). In the
last segment in the melting file, the slope was 0.1C/s;
in all other cases, the slope was 20C/s. The fluorescence
settings for gains F1, F2, and F3 were 5, 15, and 30,
respectively. The obtained data were analyzed by the
second derivative maximum method.
Results
Identification of Genomic Mutations in the ATP7A
Gene
The three patients investigated in this study were cho-
sen because they had very different clinical phenotypes
in spite of the fact that they all had a mutation at the
splice-donor site of exon 6 (IVS6,DS). Two of the pa-
tients (MD1 and MD2) had the classic severe form of
MD, whereas the third patient (OS1) had the milder
OHS form.
The ATP7A mutations of the patients were identified
with genomic DNA isolated from skin fibroblasts. In
patient MD1, an abnormal band pattern of exon 6 was
detected with single-strand conformational polymor-
phism, and, in patients MD2 and OS1, a mutation was
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Figure 1 Analyses of exon skipping in patients OS1, MD1, and
MD2. The region from exon 4 to exon 9 in theATP7A cDNA sequence
was PCR-amplified from cDNA obtained from the three patients (see
Materials and Methods). cDNA from an unaffected person was used
as a control (C). The PCR products were separated on a 3%Metaphor
gel and visualized by ethidium bromide staining. LaneM,fX174DNA-
HaeIII digest.
Table 2
Molecular Findings and Phenotype Related to Three Patients with IVS6,DS Mutations
Individual Nucleotide Sequence at IVS6,DSa Effect on mRNA Cryptic Splice-Site Sequencea,b Phenotype
Control GTTgtaagtaagat Normal mRNA Normal




MD1 GTTgtaagtaagatrGTTataagtaagat Skipping of exon 6, leading
to frameshift
MD
Skipping of exons 6 and 7,
leading to frameshift
Cryptic splice site, leading
to frameshift
GTTATAAgtaagat (exon 6 en-
larged with 4 bp)
MD2 GTTgtaagtaagatrGTTgtaaataagat Skipping of exon 6, leading
to frameshift
MD
Skipping of exons 6
and 7, leading to frame-
shift





(exon 6 enlarged with 50 bp)
a Lowercase letters indicate sequence in introns, whereas uppercase letters indicate sequence in exons.
b Boldface letters indicate the sequence included in exon 6 caused by the new exon/intron boundaries.
predicted with dideoxy fingerprinting. To identify the
mutations, exon 6, in each patient, was amplified with
intron-specific primers and sequenced on both strands
with the same primers. The normal sequence of splice-
donor site of exon 6 is TTgtaagtaaga (Dierick et al.
1995; Tu¨mer et al. 1995). In patient OS1, one of two
4-bp tandem repeats (taag) was deleted at the splice-
donor site, whereas patients MD1 and MD2 contained
base pair substitutions at positions 1 and 5, respec-
tively (table 2).
Exon Skipping in the Three Patients
The predicted effect of a mutation at the IVS6 donor
site is the skipping of exon 6. To determine whether exon
6 was skipped in all three patients, a cDNA segment
from exon 4 to exon 9 was amplified by RT-PCR (fig.
1). Amplification of the control mRNA from an unaf-
fected individual resulted in a single product of normal
size (1,300 bp), but the results obtained from the three
patients diverged from the normal. The OS1 patient had
two transcripts, a major product of 1,150 bp, and a
minor product of 1,300 bp. Patient MD1 revealed three
transcripts: a major product of 1,150 bp and two minor
products of 1,300 bp and 1,000 bp, respectively. Patient
MD2 had a 1,150-bp major product and a 1,000-bp
minor product, and a smear was observed at 1,300 bp
instead of a distinct band. Sequencing of the 1,150-bp
major product of each patient revealed skipping of exon
6, since exons 5 and 7 were precisely spliced. The 1,000-
bp band observed in both of the patients with MD was
a consequence of concomitant skipping of exons 6 and
7. Skipping of exon 6 alone (164 bp) or in combination
with exon 7 (164  162 bp) leads to a shift in reading
frame, thus resulting in a premature termination of
translation. Attempts to sequence the 1,300-bp bands
present in patients OS1 and MD1 were not successful
because of contamination with the major bands lacking
exon 6.
Characterization of Exon 6–Containing ATP7A
Transcripts
It was crucial to determine whether the normal or a
cryptic splice site was activated in the apparently normal
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Figure 2 Amplification of exon 6–containing transcripts from
patients OS1, MD1, and MD2. Exon 6–containing cDNAs from three
patients were amplified by the use of primers located in exons 6 and
9 (see Materials and Methods). cDNA obtained from an unaffected
person was used as a control (C). The PCR products were separated
on a 3% Metaphor gel and visualized by ethidium bromide staining.
Lane M, fX174DNA-HaeIII digest; lane L, 50-bp DNA ladder (Gibco
BRL).
transcript that gave rise to the 1,300-bp PCR product
in patients OS1 and MD1. Furthermore, it should be
clarified whether a normal transcript could have been
present in the 1,300-bp region of the gel, where a smear
was observed instead of a distinct band in patient MD2.
To investigate these issues, we performed RT-PCR with
primers located in exons 6 and 9, which exclusively
would allow amplification of exon 6–containing cDNAs,
even though they were in low abundance (fig. 2).
The size of the RT-PCR product of the patients OS1
and MD1 and of the control individual was ∼450 bp.
However, in the sample from patientMD2, a larger band
of ∼500 bp was observed. Sequencing of the RT-PCR
product from patient OS1 revealed a correctly spliced
exon 6–containing product, as was the case with the
control individual. The RT-PCR product from patient
MD1 represented an alternatively spliced transcript that
used a cryptic donor site, leading to an extension of exon
6 with four nucleotides. Sequencing of the 500-bp frag-
ment from patient MD2 showed activation of another
cryptic splice site, resulting in enlargement of exon 6 by
50 nucleotides. Use of the cryptic splice sites in both
cases causes a frameshift, resulting in premature termi-
nation of the reading frame. Furthermore, examination
of the sequences showed that both transcripts were
spliced at the first available cryptic splice site down-
stream of the mutations (table 2).
In summary, these results showed that the OHS pa-
tient could be clearly distinguished from theMDpatients
by the presence of some amount of correctly spliced
ATP7A mRNA. The amount of normal transcript in the
OHS patient was determined by two different quanti-
tative RT-PCR–based methods, as described in the fol-
lowing two sections.
Quantitation of ATP7A mRNA by Competitive RT-PCR
The amount of correctly spliced ATP7A mRNA in
cells from the patient with OHS was determined by com-
petitive RT-PCR, in which reverse transcription of the
mRNA is followed by competitive PCR on the generated
cDNA. In competitive PCR, a DNA fragment containing
the same primer template sequences as the target com-
petes for primer binding and amplification. The amount
of target DNA in a PCR reaction can thus be estimated
from the amount of PCR product formed from target
DNA relative to the amount of PCR product generated
from a known amount of homologous competitor DNA
(Bouaboula et al. 1992; Nedelman et al. 1992; Siebert
and Larrick 1992).
As competitor to ATP7A cDNA we used a plasmid,
pMNKD, containing an ATP7A cDNA fragment from
exon 4 to exon 6 with an internal deletion of 30 bp.
With the PCR primers MNK-1 and MNK-2, amplifi-
cation of the ATP7A target and competitor DNA re-
sulted in PCR products of 383 bp or 353 bp, respectively
(fig. 3). In addition to these two products, a slowly mi-
grating third product appeared. This band apparently
represented heteroduplexes formed between target and
competitor PCR products, because it was resolved into
two bands of 383 and 353 bp when excised and elec-
trophoresed on a denaturing polyacrylamide gel (data
not shown). Formation of heteroduplexes frequently oc-
curs when the competitor DNA is homologous to the
target (Henco and Heibey 1990).
The amount of ATP7A mRNA was normalized to the
amount of 18S rRNA in the same sample determined
by competitive RT-PCR. We chose 18S rRNA as an in-
ternal standard because the abundance of actin mRNA,
which is frequently used for this purpose, is known to
be altered in people with MD (Hamalainen et al. 1996).
As competitor in the 18S rRNA determinations, we used
a plasmid, p18SD, containing an 18S cDNA fragment
with an internal deletion of 133 bp. With the 18S-1 and
18S-2 primers (table 1), the target RNA gave rise to an
RT-PCR product of 735 bp, whereas the competitor gave
a product of only 602 bp (fig. 4A,B).
As shown in figure 3C, the amount of competitor
DNA required to give equal formation of competitor
and target PCR products was ∼60-fold higher for the
control RNA sample compared with the RNA sample
from the OHS patient. However, the determination of
18S rRNA (fig. 4C) indicated that the concentration of
total RNA in the control sample was slightly higher
(∼20%). Taking this into account, we estimate from this
experiment that the amount of correctly spliced ATP7A
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Figure 3 Determination of the amount of ATP7A transcript in
patient OS1 by competitive RT-PCR. Total RNA isolated from patient
OS1 and control fibroblasts, respectively, was used for the synthesis
of cDNA. By use of primers MNK-1 and MNK-2, equal amounts of
cDNA were amplified in the presence of increasing amounts of ho-
mologous ATP7A competitor DNA, pMNKD (from left to right).
Quantitation of the reaction products was accomplished by labeling
with a-[32P]-dCTP included in the PCR reactions. A, Ethidium bro-
mide–stained agarose gel with separated ATP7A RT-PCR products
from control fibroblast. “T” and “C” indicate the positions of the
target and competitor PCR products, respectively, and HD represents
a heteroduplex formed between these. B, Ethidium bromide–stained
agarose gel with separated ATP7A RT-PCR products from patient
OS1. C, Ratio of PCR products generated from target and competitor
DNA, respectively, as a function of the amount of competitor plasmid
DNA added to the PCR reactions. The amount of the two different
products in the heteroduplex band was taken into account in the cal-
culation of the product ratios. The ratio of target/competitor product
has been plotted only for lanes in which both signals are above back-
ground—that is, lanes 2–7 in the OHS experiment and lanes 4–9 in
the control experiment.
mRNA in the patient with OHS is ∼2% of the level
found in control cells. Two similar experiments with
different samples of either total RNA or polyA-contain-
ing messenger RNA also yielded estimates in the range
of 2%–4% of the normal level (data not shown).
Quantitation of ATP7A mRNA by Real-Time
Monitoring of the Formation of Fluorescent RT-PCR
Products
It was remarkable that the tiny amount of normal
ATP7A mRNA in the patient with OHS was apparently
sufficient to permit development of themilder phenotype
as opposed to the more severe symptoms of classic MD.
To validate this result, we measured the relative amount
of exon 6–containing ATP7A transcript by another
method, which involved real-time monitoring of the for-
mation of fluorescent RT-PCR products in a LightCycler
apparatus (see Materials and Methods). By this method,
we determined the threshold number of PCR cycles re-
quired to give detectable exponential accumulation of
PCR product for different amounts of input cDNA de-
rived from OS1 or control RNA samples. These exper-
iments were performed with mRNA samples because we
observed an inhibition of the PCR reactions if samples
of total RNA were used. Consequently, we could not
use 18S rRNA for normalization, so instead we mea-
sured the amount of GAPDH mRNA in parallel ampli-
fication reactions.
As shown in figure 5A, the threshold cycle numbers
for the OS1 sample were comparable to the values ob-
tained for control samples that were 50-fold more dilute.
However, the determinations of GAPDH mRNA (fig.
5B) indicated that the RNA sample from the control
cells was 2.5-fold more concentrated than the OS1
sample. Thus, the relative amount of correctly spliced
ATP7A mRNA in patient OS1 is estimated from this
experiment to be ∼5% of the normal level. In another
experiment using this methodology, an estimate of 2.5%
was obtained (data not shown). Thus, cells from patient
OS1 were found to contain 20- to 50-fold less correctly
spliced ATP7A mRNA than did normal control cells, as
determined both by competitive RT-PCR and by
LightCycler amplifications.
Discussion
In this study, we have shown that patients with muta-
tions in the same splice donor site of the ATP7A gene
may have different clinical phenotypes—classic MD or
milder OHS—depending on the presence of a normal
transcript. In the patients with MD who we studied,
normal ATP7A mRNA was not present at all, but in the
patient with OHS, normally processed transcript could
be detected, albeit in severely reduced amounts corre-
sponding to 2%–5% of the normal level.
The consensus sequence for a 5′ splice-donor site is
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Figure 4 Determination of the amount of 18S rRNA by com-
petitive RT-PCR. Total RNA isolated from OS1 and control fibro-
blasts, respectively, was used for the synthesis of cDNA. By use of
primers 18S-1 and 18S-2, equal amounts of cDNA were amplified in
the presence of increasing amounts of homologous 18S competitor
DNA, p18SD (from left to right). Reaction products were quantitated
as in figure 3. A, Ethidium bromide–stained agarose gel with separated
18S RT-PCR products from control fibroblast. T and C indicate the
positions of target and competitor PCR products, respectively. B, Eth-
idium bromide–stained agarose gel with separated 18S RT-PCR prod-
ucts from patient OS1.C,Ratio of PCR products generated from target
and competitor DNA, respectively, as a function of the amount of
competitor plasmid DNA added to the PCR reactions. The ratio of
target/competitor product has been plotted only for lanes in which
both signals are above background—that is, lanes 4–7 in either
experiment.
A58G78g100t100a/g96a71g84t47, where exon nucleotides are
shown in uppercase and intron nucleotides in lowercase
letters, and the numbers indicate the percentage occur-
rence of the different nucleotides (Ketterling et al. 1999).
The wild-type sequence of the splice-donor site of exon
6 is TTgtaagt (Dierick et al. 1995; Tu¨mer et al. 1995);
that is, the junction matches the consensus sequence
perfectly, except for the two nucleotides in the exon. It
is noteworthy that the mutations in the two MD pa-
tients (TTataagt in patient MD1 and TTgtaaat in pa-
tient MD2) affected two of the most strongly conserved
nucleotides in the splice site consensus sequence,
whereas the splice site in patient OS1 (TTgtaaga) de-
viated from the wild-type sequence at the least con-
served position (6) in the intron. This may explain
the use of cryptic splice sites in the patients with MD
whom we studied, whereas some correctly spliced
ATP7A transcripts could be detected in the patient with
OHS.
To our knowledge, normal ATP7A transcripts have
not been detected in any patients suffering from classic
MD, although the presence of normal transcripts has
been reported for three of five patients with OHS with
splice-site mutations (Kaler et al. 1994; Das et al. 1995;
Levinson et al. 1996). The amount of normal transcript
was determined in only one of these cases; it was found
to be 19% of the normal level by ribonuclease protec-
tion analysis (Kaler et al. 1994). Thus, we found it re-
markable that cells from patient OS1 that we examined
in the present work contained as little as 2%–5% of
the normal amount of full-length mRNA. From the
short clinical descriptions, it is not possible to correlate
in any simple way the severity of the clinical symptoms
of these two patients with OHS with their abundance
of ATP7A mRNA. However, we do not think there is
any contradiction between these results. Rather, they
suggest that ATP7A mRNA concentrations up to 20%
of the normal level may be sufficient to permit devel-
opment of the mild OHS phenotype, whereas the MD
phenotype obtains when functional mRNA is essentially
absent. It remains to be shown how much normal tran-
script is needed to avoid disease symptoms entirely.
In two of the previously reported patients with OHS,
normal ATP7A mRNA was not present (Kaler et al.
1994; Qi and Byers 1998). In one patient, the mutation
was a single-base-pair substitution within the splice-site
sequence of exon 11 (Ser833Gly). Besides two abnor-
mal-sized transcripts, a normal-size transcript was pre-
sent, but this transcript included the mutation (Kaler et
al. 1994). This missense mutation was not within a
region coding for a conserved motif, and its effect on
the function of the protein was probably not severe. In
the patient with OHS described by Qi and Byers (1998),
a normal-size transcript was not present. The abnormal
transcript was missing exon 10, which is alternatively
spliced in normal individuals (Dierick et al. 1995). The
protein product missing transmembrane domains 3 and
4 encoded by exon 10 was localized to the endoplasmic
reticulum (Qi and Byers 1998) instead of the Golgi com-
plex, where the normal ATP7A resides (Petris et al.
1996; Yamaguchi et al. 1996; Dierick et al. 1997; Fran-
cis et al. 1998). The milder phenotype of the patient
suggests that at least some of the enzymes, other than
lysyl oxidase and dopamine b-hydroxylase, could re-
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Figure 5 Quantitation of ATP7A mRNA by real-time monitor-
ing of the formation of fluorescent RT-PCR products. cDNA was re-
verse transcribed from mRNA isolated from patient OS1’s cells or
from control cells, respectively. The amount of exon 6–containing
ATP7A transcripts or GAPDH mRNA was estimated from twofold
serial dilutions of the cDNAs. A, Plot of the threshold cycle number
for the ATP7A amplification as a function of the dilution of the input
cDNA sample. B, Plot of the threshold cycle number for the GAPDH
amplification as a function of the dilution of the input cDNA sample.
ceive copper even though ATP7A is mislocalized. Thus,
these two patients probably produced at least some par-
tially functional ATP7A protein.
In contrast, none of the present patients contained
any transcripts that are likely to encode partially func-
tional protein, which might have complicated the in-
terpretation of the results. All transcripts, including the
major exon 6–deleted transcript, identified in the two
patients suffering from classic MD could only encode
severely truncated proteins, consistent with the severe
phenotype. Except for the exon 6–deleted mRNA, the
only transcript observed in the patient with OHS was
the correctly spliced mRNA. Thus, we are confident that
the mild phenotype of this patient was due to the pres-
ence of the small amount of normal ATP7A mRNA.
In several preliminary experiments, we performedRT-
PCR amplifications with primers located in exons 4 and
9, but we were not always able to detect the exon 6–con-
taining product in patient OS1 and MD1, and we were
never able to detect it in patient MD2. This was prob-
ably because the large majority of ATP7A transcripts
lacking exon 6 was preferentially amplified at the ex-
pense of the small fraction of transcripts containing
exon 6. However, we found that this problem could be
avoided by performing RT-PCR with primers located in
exons 6 and 9, so that only exon 6–containing tran-
scripts would be amplified. This strategy may be gen-
erally useful for identification and quantitation of very
small amounts of specific mRNAs.
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